Figure 1.
Mean (a) plasma tenofovir alafenamide (TAF), (b) plasma tenofovir (TFV), (c) intracellular tenofovir diphosphate (TVF-DP), (d) plasma emtricitabine (FTC) and (e) intracellular emtricitabine triphosphate (FTC-TP) concentration–time profiles and 95% CIs. RIF, rifampicin; TDF, tenofovir disoproxil fumarate.

Mean (a) plasma tenofovir alafenamide (TAF), (b) plasma tenofovir (TFV), (c) intracellular tenofovir diphosphate (TVF-DP), (d) plasma emtricitabine (FTC) and (e) intracellular emtricitabine triphosphate (FTC-TP) concentration–time profiles and 95% CIs. RIF, rifampicin; TDF, tenofovir disoproxil fumarate.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close